| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | NT 10-Q |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 03 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Bankruptcy or Receivership +4 more
Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. |
| 02 Nov 2026 |
8-K: Regulation FD Disclosure
– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis – |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 22 Oct 2026 |
8-K: Other Events
As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indenture... |
| 19 Oct 2026 |
Form 4: Abate Kristin, Chief Accounting Officer
Sold 4,788 shares ($1.65K) |
| 14 Oct 2026 |
8-K: Other Events
As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10,... |
| 08 Oct 2026 | SCHEDULE 13G/A |
| 02 Oct 2026 |
Form 4: Abate Kristin, Chief Accounting Officer
Sold 378 shares ($450) |
| 25 Sep 2026 | SCHEDULE 13G/A |
| 25 Sep 2026 | SCHEDULE 13G/A |
| 18 Sep 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
On September 17, 2026, the Pricing Committee of the Board of Directors of Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), acting pursuant to authority delegated to it by the Board of Directors on September 10, 2026 ... |
| 11 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation +2 more
This Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026 (this “Agreement”), is entered into by and among (i) Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”) and each of the undersi... |
| 04 Sep 2026 | SCHEDULE 13G |
| 02 Sep 2026 |
Form 4: Abate Kristin, Chief Accounting Officer
Sold 19 shares ($38.4) |
| 31 Aug 2026 |
8-K: Other Events
On August 31, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced that it has submitted a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) seeking Accelerated Approval for XPOVIO® (seli... |
Loading...